Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study.
De Falco V, Colloca A, Argenziano G, Scala M, Guida M, Ottaviano M, Sergi MC, Santarpia M, Del Giudice T, Grimaldi AM, Cozzolino S, Forte M, Caraglia F, Cioli E, Esposito A, Giugliano MC, Sparano F, Iovino F, Tolone S, Docimo G, Colella G, Faenza M, Franco R, Scharf C, Russo A, Formisano L, Ciardiello D, Ascierto PA, Ciardiello F, Troiani T.
De Falco V, et al. Among authors: sparano f.
Cancer Immunol Immunother. 2026 Jul 17. doi: 10.1007/s00262-026-04466-0. Online ahead of print.
Cancer Immunol Immunother. 2026.
PMID: 42467079